Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KMDA NASDAQ:LKFT NASDAQ:OCUL NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKMDAKamada$7.50-4.0%$8.18$6.50▼$9.35$449.11M0.8454,412 shs50,084 shsLKFTLakefront Biotherapeutics American Depositary Shares$27.54-2.9%$28.60$26.42▼$37.78$1.87B0.25155,361 shs214,498 shsOCULOcular Therapeutix$8.33-7.6%$8.81$6.23▼$16.44$1.97B0.932.78 million shs2.06 million shsVCELVericel$35.01+5.1%$33.92$28.95▼$45.97$1.70B1.12625,126 shs529,975 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKMDAKamada-1.41%-1.66%-6.21%-13.77%+12.90%LKFTLakefront Biotherapeutics American Depositary Shares-2.86%+0.18%-1.64%-16.67%-5.10%OCULOcular Therapeutix-0.89%+8.51%-5.30%-17.01%+11.49%VCELVericel-1.53%-5.50%-7.73%-4.57%-21.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKMDAKamada$7.50-4.0%$8.18$6.50▼$9.35$449.11M0.8454,412 shs50,084 shsLKFTLakefront Biotherapeutics American Depositary Shares$27.54-2.9%$28.60$26.42▼$37.78$1.87B0.25155,361 shs214,498 shsOCULOcular Therapeutix$8.33-7.6%$8.81$6.23▼$16.44$1.97B0.932.78 million shs2.06 million shsVCELVericel$35.01+5.1%$33.92$28.95▼$45.97$1.70B1.12625,126 shs529,975 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKMDAKamada-1.41%-1.66%-6.21%-13.77%+12.90%LKFTLakefront Biotherapeutics American Depositary Shares-2.86%+0.18%-1.64%-16.67%-5.10%OCULOcular Therapeutix-0.89%+8.51%-5.30%-17.01%+11.49%VCELVericel-1.53%-5.50%-7.73%-4.57%-21.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKMDAKamada 3.00Buy$12.0060.11% UpsideLKFTLakefront Biotherapeutics American Depositary Shares 2.00Hold$36.5032.53% UpsideOCULOcular Therapeutix 2.79Moderate Buy$23.78185.62% UpsideVCELVericel 2.50Moderate Buy$55.4058.22% UpsideCurrent Analyst Ratings BreakdownLatest KMDA, LKFT, OCUL, and VCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026LKFTLakefront Biotherapeutics American Depositary Shares Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/15/2026KMDAKamada Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/11/2026VCELVericel Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/8/2026VCELVericel HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$64.005/8/2026LKFTLakefront Biotherapeutics American Depositary Shares Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/6/2026OCULOcular Therapeutix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$30.005/5/2026OCULOcular Therapeutix Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.004/21/2026OCULOcular Therapeutix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026VCELVericel Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$48.00 ➝ $42.004/13/2026OCULOcular Therapeutix HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.003/12/2026KMDAKamada BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKMDAKamada$180.46M2.39$0.59 per share12.79$4.68 per share1.60LKFTLakefront Biotherapeutics American Depositary Shares$1.04B1.74$0.71 per share39.05$47.57 per share0.58OCULOcular Therapeutix$52.04M35.03N/AN/A$3.07 per share2.71VCELVericel$276.26M6.47$0.58 per share60.00$7.01 per share4.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKMDAKamada$20.20M$0.3521.5412.290.7211.21%7.73%5.41%8/12/2026 (Estimated)LKFTLakefront Biotherapeutics American Depositary Shares$363.05M-$1.41N/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)OCULOcular Therapeutix-$265.94M-$1.46N/AN/AN/A-558.24%-64.28%-48.15%8/4/2026 (Estimated)VCELVericel$16.52M$0.4276.5642.19N/A7.35%6.41%4.61%7/30/2026 (Estimated)Latest KMDA, LKFT, OCUL, and VCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026KMDAKamada$0.12$0.07-$0.05$0.07$46.72 million$45.24 million5/7/2026Q1 2026VCELVericel-$0.15-$0.12+$0.03-$0.12$63.68 million$68.43 million5/6/2026Q1 2026LKFTLakefront Biotherapeutics American Depositary Shares-$1.27$0.25+$1.52$0.25$11.26 million$7.50 million3/11/2026Q4 2025KMDAKamada$0.09$0.06-$0.03$0.06$145.07 million$44.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKMDAKamada$0.192.54%N/A54.29%N/ALKFTLakefront Biotherapeutics American Depositary SharesN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ALatest KMDA, LKFT, OCUL, and VCEL DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/11/2026KMDAKamadaannual$0.253.05%3/23/20263/23/20264/7/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKMDAKamadaN/A3.331.90LKFTLakefront Biotherapeutics American Depositary SharesN/A30.4830.30OCULOcular Therapeutix0.1214.8114.73VCELVericelN/A5.184.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKMDAKamada20.38%LKFTLakefront Biotherapeutics American Depositary Shares32.46%OCULOcular Therapeutix59.21%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipKMDAKamada36.10%LKFTLakefront Biotherapeutics American Depositary Shares2.91%OCULOcular Therapeutix2.30%VCELVericel7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKMDAKamada36057.51 million36.75 millionOptionableLKFTLakefront Biotherapeutics American Depositary Shares1,31065.90 million63.98 millionOptionableOCULOcular Therapeutix230218.96 million213.92 millionOptionableVCELVericel30051.07 million47.19 millionOptionableKMDA, LKFT, OCUL, and VCEL HeadlinesRecent News About These CompaniesVericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million MoreMay 30 at 5:38 PM | finance.yahoo.comVericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 23, 2026 | americanbankingnews.comSummit Creek Advisors LLC Reduces Stock Position in Vericel Corporation $VCELMay 21, 2026 | marketbeat.comVericel Lifts 2026 Outlook After Standout QuarterMay 19, 2026 | tipranks.comVericel Corporation $VCEL Stock Position Reduced by Truist Financial CorpMay 18, 2026 | marketbeat.comWhat is HC Wainwright's Estimate for Vericel Q4 Earnings?May 11, 2026 | marketbeat.comVericel Corporation 2026 Q1 - Results - Earnings Call PresentationMay 9, 2026 | seekingalpha.comAnalysts Have Made A Financial Statement On Vericel Corporation's (NASDAQ:VCEL) First-Quarter ReportMay 9, 2026 | finance.yahoo.comVericel (VCEL) Q1 2026 Earnings TranscriptMay 9, 2026 | finance.yahoo.comVericel Q1 Earnings Call HighlightsMay 9, 2026 | marketbeat.comVericel Earnings Call Signals Accelerating Growth and MarginsMay 8, 2026 | tipranks.comVericel (NASDAQ:VCEL) Trading Down 9.1% - What's Next?May 8, 2026 | marketbeat.comVericel Corporation (VCEL) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comVericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPSMay 7, 2026 | marketbeat.comVericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue EstimatesMay 7, 2026 | zacks.comVericel (NASDAQ:VCEL) Shares Gap Up on Strong EarningsMay 7, 2026 | marketbeat.comVericel Corporation Reports 30% Revenue Growth to $68.4 Million in Q1 2026, Raises Full-Year Guidance to $326-$336 MillionMay 7, 2026 | quiverquant.comQVericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial GuidanceMay 7, 2026 | globenewswire.comVericel Q1 2026 earnings previewMay 7, 2026 | msn.comWall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a BetMay 4, 2026 | zacks.comVericel Shareholders Reaffirm Board, Pay Plan, AuditorMay 1, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKMDA, LKFT, OCUL, and VCEL Company DescriptionsKamada NASDAQ:KMDA$7.50 -0.32 (-4.03%) As of 12:57 PM Eastern This is a fair market value price provided by Massive. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT$27.54 -0.81 (-2.86%) As of 06/1/2026 04:00 PM EasternGalapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Ocular Therapeutix NASDAQ:OCUL$8.32 -0.69 (-7.60%) As of 01:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Vericel NASDAQ:VCEL$35.01 +1.68 (+5.05%) As of 01:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MGM Buyout: The House Doesn't Always Win Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for Investors How the Latest Federal Contract Boosts D-Wave's Prospects 5 Reasons to Pony Up for Pony AI Stock—and 1 Reason to Wait Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance MarketBeat Week in Review – 05/25 - 05/29 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
